Gilead, the California-headquartered firm behind anti-hepatitis B product Hepsera, has appointed Nexus Structured Communications for a two-year campaign to ‘raise awareness’ of hepatitis B among UK opinion formers.
NSC managing director Geoffrey Bowden, who reports to Hepsera UK and Ireland product manager Nigel Hughes, said: ‘Hepatitis B carries with it all the stigma associated with Aids in the early 1980s. It is essential to give hepatitis B a platform.’
Submissions to NICE for its upcoming appraisal of chronic hepatitis B treatments are due next February.
Gilead continues to retain Weber Shandwick on a global hepatitis B remit. Meanwhile, NSC has appointed former CancerBACUP head of comms Mark Winkless as associate director.